Monoclonal antibodies Anticancer therapy

1. Monoclonal antibodies Anticancer therapy

2. Lymphocytes • Produce antibodies • B-cells mature in bone marrow then concentrate in lymph nodes and spleen • T-cells mature in thymus • B and T cells mature then circulate in the blood and lymph • Circulation ensures they come into contact with pathogens and each other

3. B -Lymphocytes • There are c.10 million different B-lymphocytes, each of which make a different antibody. • The huge variety is caused by genes coding for abs changing slightly during development. • There are a small group of clones of each type of B-lymphocyte

4. B -Lymphocytes • At the clone stage antibodies do not leave the B-cells. • The abs are embedded in the plasma membrane of the cell and are called antibody receptors. • When the receptors in the membrane recognise and antigen on the surface of the pathogen the B-cell divides rapidly. • The antigens are presented to the B-cells by macrophages

5. B -Lymphocytes

6. B -Lymphocytes • Some activated B cells  PLASMA CELLS these produce lots of antibodies, < 1000/sec • The antibodies travel to the blood, lymph, lining of gut and lungs. • The number of plasma cells goes down after a few weeks • Antibodies stay in the blood longer but eventually their numbers go down too.

7. B -Lymphocytes • Some activated B cells  MEMORY CELLS. • Memory cells divide rapidly as soon as the antigen is reintroduced. • There are many more memory cells than there were clone cells. • When the pathogen/infection infects again it is destroyed before any symptoms show.

8. What are antibodies An antibody is a protein used by the immune system to identify and neutralize foreign objects like bacteria and viruses. Each antibody recognizes a specific antigen unique to its target. Monoclonal antibodies (mAb) are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cell. Polyclonal antibodiesare antibodies that are derived from different cell lines. Isotypes According to differences in their heavy chain constant domains, immunoglobulins are grouped into five classes, or isotypes: IgG, IgA, IgM, IgD, and IgE. IgG: IgG1 (66%), IgG2 (23%), IgG3 (7%) and IgG4 (4%) , blood and tissue liquid. IgA:IgA1 (90%) and IgA2 (10%), stomach and intestines IgM: normally pentamer, ocassionally hexamer, multiple immunoglobins linked with disulfide bonds IgD:1% of proteins in the plasma membranes of B-lymphocytes, function unknown IgE: on the surface of plasma membrane of mast cells, play a role in immediate hypersensitive and denfensive for parasite

9. The structure of antibodies • http://www.path.cam.ac.uk/~mrc7/igs/mikeimages.html

10. Antibodies • Also known as immunoglobulins • Globular glycoproteins • The heavy and light chains are polypeptides • The chains are held together by disulphide bridges • Each ab has 2 identical ag binding sites – variable regions. • The order of amino acids in the variable region determines the shape of the binding site

11. How Abs work • Some act as labels to identify antigens for phagocytes • Some work as antitoxins i.e. they block toxins for e.g. those causing diphtheria and tetanus • Some attach to bacterial flagella making them less active and easier for phagocytes to engulf • Some cause agglutination (clumping together) of bacteria making them less likely to spread

12. Different Immunoglobulins

14. History of Mab development • 1890 Von Behring and kitasato discovered the serum of vaccinated persons contained certain substances, termed antibodies • 1900 Ehrlich proposed the “ side-chain theory” • 1955 Jerne postulated natural selection theory. Frank Macfarlane Burnet expended. • Almost the same time, Porter isolated fragment of antigen binding (Fab) and fragment crystalline (Fc) from rabbit y-globulin. • 1964 Littlefield developed a way to isolate hybrid cells from 2 parent cell lines using the hypoxanthine-aminopterin-thymidine (HAT) selection media. • 1975 Kohler and Milstein provided the most outstanding proof of the clonal selection theory by fusion of normal and malignant cells • 1990 Milstein produced the first monoclonal antibodies.

15. The types of mAb designed • Murine source mAbs: rodent mAbs with excellent affinities and specificities, generated using conventional hydrioma technology. Clinical efficacy compromised by HAMA(human anti murine antibody) response, which lead to allergic or immune complex herpersensitivities. • Chimeric mAbs: chimers combine the human constant regions with the intact rodent variable regions. Affinity and specificity unchanged. Also cause human antichimeric antibody response (30% murine resource) • Humanized mAbs: contained only the CDRs of the rodent variable region grafted onto human variable region framework

16. Chemotherapy Shortcomings: • Nature of cytotoxin • Lack of in vivo selectivity • The mechanism of anti-proliferation on cells cycle, rather than specific toxicity directed towards particular cancer cell • Host toxixity: treatment discontinued, most of them had bad side-effects, such as no appetites, omit, lose hair

17. Monoclonal antibodies for cancer treatment Three mechanisms that could be responsible for the cancer treatment. • mAbs act directly when binding to a cancer specific antigen and induce immunological response to cancer cells. Such as inducing cancer cell apoptosis, inhibiting growth, or interfering with a key function. • mAbs was modified for delivery of a toxin, radioisotope, cytokine or other active conjugates. • it is also possible to design bispecific antibodies that can bind with their Fab regions both to target antigen and to a conjugate or effector cell

18. mAbs treatment for cancer cells ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependent cell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129

19. Strategy of a direct or in direct induction of apoptosis in targeted cancer cells • mAbs target growth factor receptors to exert a direct effect on the growth and survival of the cancer cells by antagonizing ligand-receptor signaling. • mAbs can target to cell surface antigens and directly elicit apoptotic signaling. Dale L Ludwig, etal. Oncogene(2003) 22, 9097-9106

20. Until Feb 28, 2005, 18 mAbs were approved by FDA, which were applied in the treatment of organ transplant, Cancer, Asthma, Hematopoietic malignancies and psoriasis. The first approved mAbs was OKT-3, which is a murine IgGa2 protein to deplete T cells in patients with acute rejection of renal allotransplant. HAMA response Jancie, M Recheit, etal. Nature biotechnology, 2005, Sep,Vol. 23, No.9 Stamatis-Nick C. J Allergy Clin. Immunol, Oct. 2005

21. mAbs development • Phage display library: construction ofVH and VL gene libaries and expression of them on a filamentous bacterophage. The phage expressing an antigen-bonding domain specific for a particular antigen to screen the mAbs. • Transgenic plants: transgenic tobacco plants to produce IgA. • Transgenic animals: transgenic mouse to make humanized IgG. (Abgenix,CA)

22. Conventional production of mAbs The hybridoma technology: spleen cells from immunized mice are fused with the murine myeloma cells. The several process had been developed at large scale. According to the different cell culture methods, it can calisifed into four fields • Robottle cell culture process. • Membrane binded cell culture process • Microcarrier cell culture process • Suspended cell culture process